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Ciliary neurotrophic factor (CNTF), originally described as a neurocytokine that could
support the survival of neurons, has been recently found to alleviate demyelination,
prevent axon loss, and improve functional recovery in a rat model of acute experimental
autoimmune encephalomyelitis (EAE). However, poor penetration into the brain
parenchyma and unfavorable side effects limit the utility of CNTF. Here, we evaluated
the therapeutic potential of a protein downstream of CNTF, regeneration gene protein
2 (Reg-2). Using multiple morphological, molecular biology, and electrophysiological
methods to assess neuroinflammation, axonal loss, demyelination, and functional
impairment, we observed that Reg-2 and CNTF exert similar effects in the acute phase
of EAE. Both treatments attenuated axonal loss and demyelination, improved neuronal
survival, and produced functional improvement. With a smaller molecular weight and
improved penetration into the brain parenchyma, Reg-2 may be a useful substitute for
CNTF therapy in EAE and multiple sclerosis (MS).
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INTRODUCTION
Multiple sclerosis (MS) is a neurodegenerative disease of the central nervous system (CNS) that
is characterized by CNS inflammation, demyelination, axonal degeneration, neuron loss, and
neurological deficits (Bannerman et al., 2005). The corresponding animal model, experimental
autoimmune encephalomyelitis (EAE), is an experimental paradigm that is widely used for the
study of MS (Hou et al., 2012).
A previous study showed that treatment with ciliary neurotrophic factor (CNTF) robustly
promoted myelin formation, reduced perivascular T cell infiltration, and limited the extent
of microglial activation in EAE (Kuhlmann et al., 2006). This study of CNTF also reported
significantly higher numbers of oligodendrocytes, axons, and neurons in EAE mice that
had been treated with high doses of CNTF. However, CNTF is a relatively large molecule
(molecular mass: 25 kDa; Webster, 1997) and does not easily cross the blood-brain barrier
(BBB). Previous primate and rodent studies have also suggested that CNTF needs to be delivered
directly to the parenchyma of the striatum to be effective (Emerich, 2004). Moreover, the adverse
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effects of CNTF treatment, such as fever, malaise, and weight loss,
limit its potential clinical use (Kuhlmann et al., 2006).
Regeneration gene protein 2 (Reg-2) is a relatively small
(molecular mass: 16 kDa) secreted protein that is expressed
in motoneurons during development and induced by CNTF-
related cytokines in the adult CNS (Nishimune et al., 2000).
Reg-2 has been shown to facilitate the regeneration of
motor and sensory neurons after peripheral nerve injury
in the adult rat, and to act as an essential intermediate
neurotrophic factor in the pathways through which CNTF
supports motor neuron survival during development (Averill
et al., 2002). We recently demonstrated the neuroprotective
effects of Reg-2 in a rodent model of spinal cord injury
(Fang et al., 2010, 2011). Moreover, in preliminary experiments,
we investigated the adverse effects of intravenously delivered
Reg-2 naïve rats and did not observe fever, lackluster hair
or hair loss, haggard appearance, or weight loss (data not
shown). However, whether Reg-2 can be used as a suitable
substitute for CNTF in the rodent model of EAE requires
confirmation.
In this study, we first analyzed the permeability of the BBB
to Reg-2 and CNTF, and then delivered Reg-2 or CNTF directly
into the lateral ventricle of EAE rats to avoid confounding effects
due to differences in CNS penetration. We subsequently assessed
the degree of inflammation, axonal loss, demyelination, and
functional impairment in treated EAE rats.
MATERIALS AND METHODS
Animals
Fifteen adult male Sprague-Dawley rats and 56 adult male Lewis
rats weighing 250–300 g were obtained from the Laboratory
Animal Services Centre of Zhejiang University. Rats were
housed in temperature- and humidity-controlled chambers and
had access to food and water ad libitum. All animal procedures
used in this study were carried out in accordance with the
National Institutes of Health Guide for the Care and Use of
Laboratory Animals, and with approval from the Animal Ethics
Committee of Zhejiang University.
Analysis of the Permeability of the
Blood-Brain Barrier to Reg-2 and CNTF
Recombinant Reg-2 (16 kDa) and CNTF (25 kDa) labeled
with 13C6-Leucine were purchased from GL Biochem Ltd.
(Shanghai, China). Ten Sprague-Dawley rats were divided
randomly into two groups and anesthetized using 40 mg/kg
pentobarbital. Subsequently, a bolus (1 mL) containing 13C6-
labeled Reg-2 or CNTF in 0.9% saline (1 mg/mL) was
rapidly injected into the brachial vein. Rats were sacrificed
1 h after injection, the brain was collected, and the choroid
plexus and meninges were carefully removed. Tissues were
then lyophilized and dry weights were determined using a
microbalance (Poduslo and Curran, 1996). Tissues were lysed
in a solution containing 1% Triton X-100 and a protease
inhibitor cocktail. Protein mixtures were then separated on
an SDS-PAGE gradient gel (7.5–15%), stained with Coomassie
blue, and the bands of the correct molecular weight proteins
were identified (Zhang et al., 2012). Liquid chromatography-
mass spectrometric (LC-MS) analysis was used to monitor the
amount of the 13C6-leucine labeling in each group. Scans of the
entire LC-MS/MS data set were analyzed using Qual Browser
Xtract Software (Thermo Scientific, Bremen, Germany; Romijn
et al., 2005). Values from five rats in the control group, which
received only 0.9% saline, were used for subtracting background
values.
Animals and EAE Induction
Of 56 Lewis rats, eight were used as normal controls and
the remaining 48 were randomly divided into three groups:
a vehicle (saline)-treated group, a Reg-2-treated group, and a
CNTF-treated group. Reg-2 was synthesized by Shanghai Science
Peptide Biological Technology Co., Ltd (Shanghai, China)
and CNTF was obtained from PeproTech Inc. (Rocky Hill,
NJ, USA).
EAE was induced prior to the initiation of treatments with
a subcutaneous injection of 0.2 mL of a 1:1 mixture of guinea
pig spinal cord homogenate (GPSCH) and complete Freund’s
adjuvant (CFA) containing 0.5 mg of heat-killedMycobacterium
tuberculosis (Difco Laboratories, Detroit, MI, USA). Rats in the
normal control group were injected with CFA emulsified 1:1 with
0.9% saline. Immediately thereafter and again 48 h later, each
rat received an intraperitoneal injection of 300 ng Pertussis toxin
in 0.1 mL sterile water (Sigma-Aldrich, St. Louis, MO, USA; Ma
et al., 2010; Yin et al., 2010).
Animals were assessed for clinical signs of disease by
blinded observers on a daily basis. Assessments were initiated
immediately following EAE induction on day 0 and continued
until the time of sacrifice. Disease severity was graded using a
0–5 scale: grade 0 = no signs of paralysis, grade 1 = partial loss
of tail tonicity, grade 2 = complete loss of tail tonicity, grade
3 = unsteady gait andmild paralysis, grade 4 = hind limb paralysis
and incontinence, and grade 5 = moribund or death (Yu et al.,
2010).
Preparation of Osmotic Pumps for Drug
Delivery
CNTF, Reg-2, or vehicle was delivered continuously over a
2-week period via implanted Alzet osmotic minipumps (pump
model 2002; Alzet, Billerica, MA, USA; 1 mg/ml, 0.5 µL/h).
Pumps were prepared under sterile conditions, filled with 0.9%
saline (for the vehicle-treated group: n = 16), or Reg-2 or CNTF
in saline (1 mg/ml, n = 16 per group; Cui et al., 2004; Fang
et al., 2011), and primed overnight at room temperature. All
pumps were implanted immediately after EAE induction. The
drug delivery process has been previously described (Fang et al.,
2013).
Neurophysiological Examination
Cortical somatosensory evoked potentials (c-SEPs) and cortical
motor evoked potentials (c-MEPs) were recorded at 2 weeks
(peak EAE severity in vehicle-treated rats) and 8 weeks (recovery
stage in vehicle-treated rats) post-immunization in five rats
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from each group immediately prior to sacrifice. Recordings were
performed by blinded observers as previously described (c-SEP
procedure: Troncoso et al., 2000; Devaux et al., 2003; All et al.,
2009; Fang et al., 2013; c-MEP procedure: Bolay et al., 2000; Fang
et al., 2013).
Perfusion and Tissue Processing
Animals were sacrificed at 2 weeks and 8 weeks post-
immunization (five animals per time point per group). Half of
the brain and spinal cord tissues from each animal were prepared
for histological assessment and immunohistochemical and
immunofluorescence staining, and the remaining tissues were
examined using transmission electron microscopy. Perfusion
and tissue processing were performed as previously described
(Han et al., 2013; Zhang et al., 2014).
Histological Assessment
Digital photomicrographs were obtained at 200× magnification
in three visual fields per section. Cresyl violet (Nissl) staining was
used to assess inflammation and neuronal survival. Inflammatory
cell infiltration was assessed according to the following scale
(Romijn et al., 2005): 0 = no inflammation, 1 = cellular
infiltration proximal to the blood vessels and meninges, 2 = mild
cellular infiltration into the parenchyma (1–10 cells/section),
3 = moderate cellular infiltration into the parenchyma
(11–100 cells/section), and 4 = severe cellular infiltration
into the parenchyma (100+ cells/section). For neuronal counts,
large multipolar spinal cord anterior horn motoneurons and
TABLE 1 | CNTF treatment and Reg-2 treatment reduce c-SEP latency and
increase c-SEP amplitude at 2 weeks post-immunization.
2 weeks
Latency (ms)
Wave amplitude
Groups N P (µV mean ± SD)
Normal 15.53 ± 1.48∗∗ 20.45 ± 2.33∗∗ 1.22 ± 0.25∗∗
EAE 26.91 ± 3.32 35.73 ± 3.54 0.39 ± 0.03
CNTF 21.35 ± 1.17∗ 27.1 ± 0.77∗ 0.72 ± 0.16∗
Reg-2 18.2 ± 0.71∗ 24.78 ± 0.77∗ 0.65 ± 0.19∗
∗P < 0.05 vs. vehicle-treated EAE rats. ∗∗P < 0.01 vs. vehicle-treated EAE rats.
N, negative deflection; P, positive deflection.
TABLE 2 | CNTF treatment and Reg-2 treatment reduce c-SEP latency and
increase c-SEP amplitude at 8 weeks post-immunization.
8 weeks
Latency (ms)
Wave amplitude
Groups N P (µV mean ± SD)
Normal 13.78 ± 1.90∗∗ 19.23 ± 1.64∗∗ 2.60 ± 0.24∗∗
EAE 25.58 ± 6.36 37.13 ± 1.10 0.58 ± 0.08
CNTF 18.95 ± 4.57∗ 26.13 ± 1.15∗ 0.90 ± 0.26∗
Reg-2 15.97 ± 0.12∗ 21.53 ± 0.21∗ 1.30 ± 0.40∗∗
∗P < 0.05 vs. vehicle-treated EAE rats. ∗∗P < 0.01 vs. vehicle-treated EAE rats.
N, negative deflection; P, positive deflection.
TABLE 3 | CNTF treatment and Reg-2 treatment reduce c-MEP latency
and increase c-MEP amplitude at 2 weeks post-immunization.
2 weeks
Groups Latency (ms) Wave amplitude
(µV mean ± SD)
Normal 5.15 ± 0.17∗ 3.02 ± 0.73∗∗
EAE 7.73 ± 2.31 0.21 ± 0.01
CNTF 5.8 ± 0.25∗ 2.13 ± 0.23∗∗
Reg-2 5.57 ± 0.26∗ 2.03 ± 0.38∗∗
∗P < 0.05 vs. vehicle-treated EAE rats. ∗∗P < 0.01 vs. vehicle-treated EAE rats.
TABLE 4 | CNTF treatment and Reg-2 treatment reduce c-MEP latency
and increase c-MEP amplitude at 8 weeks post-immunization.
8 weeks
Groups Latency (ms) Wave amplitude
(µV mean ± SD)
Normal 3.56 ± 0.77∗∗ 3.78 ± 1.06∗∗
EAE 6.8 ± 0.15 0.22 ± 0.08
CNTF 5.3 ± 0.08∗ 1.2 ± 0.23∗∗
Reg-2 5.2 ± 0.14∗ 1.63 ± 0.15∗∗
∗P < 0.05 vs. vehicle-treated EAE rats. ∗∗P < 0.01 vs. vehicle-treated EAE rats.
pyramid-shaped precentral gyrus motoneurons were counted if
the cells displayed a well-defined nucleolus and a cell body with
adequate amounts of endoplasmic reticulum.
Immunohistochemical staining of myelin basic protein
(MBP) was used to evaluate the degree of demyelination.
FIGURE 1 | Ciliary neurotrophic factor (CNTF) treatment and
regeneration gene protein 2 (Reg-2) treatment similarly improve the
clinical progression of experimental autoimmune encephalomyelitis
(EAE). The clinical progression of EAE was attenuated in rodents treated with
CNTF or Reg-2, as measured by disease scoring. ∗P < 0.05 vs.
vehicle-treated group at the same time point. ∗∗P < 0.01 vs. vehicle-treated
group at the same time point. A delay in the onset of EAE symptoms and a
postponed peak stage were observed in CNTF- and Reg-2-treated rats.
During the onset and recovery stages, clinical scores were lower in
Reg-2-treated rats than in CNTF-treated rats (#P < 0.05 vs. the CNTF-treated
group).
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Demyelination was scored as follows (Yin et al., 2010):
0 = normal white matter, 1 = rare foci of demyelination,
2 = few areas of demyelination, 3 = confluent perivascular or
subpial demyelination, 4 = massive perivascular and subpial
demyelination involving one half of the spinal cord, with the
presence of cellular infiltrates into the CNS parenchyma, and
5 = extensive perivascular and subpial demyelination involving
the whole cord section, with the presence of cellular infiltrates
into the CNS parenchyma.
Bielschowsky’s silver staining was performed to estimate
axonal loss (Bolay et al., 2000; Han et al., 2013) and assessed
according to the following scale (Yin et al., 2010): 0 = no loss,
1 = few foci of superficial loss involving less than 25% of tissue,
2 = foci of deep axonal loss involving greater than 25% of tissue,
and 3 = diffuse and widespread axonal loss.
Immunohistochemical and
Immunofluorescence Staining
Immunohistochemical staining with anti-CD4 (1:500,
Abcam, Cambridge, MA, USA), anti-COX-2 (COX-2;
1:1000, BioVision, Milpitas, CA, USA), anti-activated
caspase-3 (1:500; Cayman Chemical, Ann Arbor, MI,
USA), anti-NF-κB p65 (1:500, Abcam), and anti-MBP
(1:500, Abcam), and immunofluorescence staining with
polyclonal anti-BCL-2 (1:200; Santa Cruz, Dallas, TX,
USA), anti-TNF-α (1:1000; ProSci Inc., San Diego, CA,
USA), anti-activated BAX (1:200; Santa Cruz), anti-
GAP43, and anti-CD68/ED1 (1:100; Santa Cruz) were
performed as previously described (Cui et al., 2004). Double-
immunostaining was performed using anti-CD4 (1:500, Abcam,
Cambridge, MA, USA, green) and anti-CCR3 (1:500, Abcam,
Cambridge, MA, USA) to identify Th2-polarized cells. Primary
antibody omission controls were performed as negative
controls.
Five sections from the motor cortex and bilateral anterior
horns of the spinal cord for each animal were randomly selected
and images were photographed under 20× magnification in
three vision fields per section. The numbers of cells positive for
COX-2-, NF-κB p65, GAP43, BAX, BCL-2 and caspase-3 were
counted (cells positive for GAP43, BAX, and BCL-2 were counted
via immunofluorescence staining and cells positive for COX-2-,
NF-κB p65, and caspase-3 were counted using a counter-staining
method).
Electron Microscopy
Processing for electron microscopy was performed as previously
described (Bolay et al., 2000; Han et al., 2013). Images were
captured in different regions of the motor cortex and lumbar
FIGURE 2 | CNTF treatment and Reg-2 treatment inhibit inflammatory cell infiltration. At 2 weeks post-immunization, the infiltration of CD4+ T lymphocytes
(A–D) and CD68+ macrophages (E–H) was observed proximal to blood vessels and in the central nervous system (CNS) parenchymata of vehicle-treated rats. Both
CNTF and Reg-2 treatments alleviated inflammatory cell infiltration. (A–D) Immunostaining for CD4 (a marker of extravasated T lymphocytes) and counterstaining
with hematoxylin. (E–H) Immunofluorescence staining for CD68 (a marker of activated microglia/extravasated macrophages). (I,J) Double immunostaining for CD4
(green) and CCR3 (red), a marker for Th2-polarized cells. Scale bar = 100 µm. The arrow shows infiltrating inflammatory cells surrounding blood vessels in a
“perivascular cuffing” formation. (K,L) CNTF and Reg-2 treatments attenuated CNS inflammation at 2 weeks (K) and 8 weeks (L) post-immunization, as estimated
by inflammation score. (a) P < 0.05 vs. vehicle-treated EAE rats; (b) P < 0.05 vs. CNTF-treated EAE rats.
Frontiers in Neuroanatomy | www.frontiersin.org 4 May 2016 | Volume 10 | Article 50
Jiang et al. Reg-2 and Autoimmune Encephalomyelitis
FIGURE 3 | CNTF treatment and Reg-2 treatment reduce demyelination. Sections were stained for myelin basic protein (MBP) and counterstained with
hematoxylin (A–G). (H,I) The effect of CNTF and Reg-2 treatments on myelination at 2 weeks (H) and 8 weeks (I) post-immunization, as estimated by demyelination
score. (a) P < 0.05 vs. vehicle-treated EAE rats; (b) P < 0.05 vs. CNTF-treated EAE rats. Scale bar = 100 µm.
spinal cord. All histological assessments were performed in a
blinded fashion.
Quantification of Cytokine Levels by
Enzyme-Linked Immunosorbent Assay
(ELISA)
Peripheral blood samples were collected from rats sacrificed
by decapitation at 2 weeks and 8 weeks post-immunization
(n = 3 per time point per group). ELISAs for IL-2 (Abcam), IL-4
(Abcam), TGF-β (R&D Systems), and IFN-γ (BioLegend Inc.)
were performed according to manufacturer specifications (Bolay
et al., 2000; Han et al., 2013). Optical density was measured at 450
nm and analyzed using GraphPad Prism 4 (GraphPad Software,
Inc., San Diego, CA, USA).
Western Blotting
Rats were sacrificed by decapitation at 2 weeks and 8 weeks
post-immunization (n = 3 per time point per group). Whole
brain cortical tissue and 10 mm lumbar spinal cord segments
were prepared for western blotting. Processing was performed as
previously described (Bolay et al., 2000; Han et al., 2013). Primary
antibody omission controls were performed as negative controls.
Statistical Analysis
Differences in protein expression were analyzed using a 2-way
ANOVA followed by post hoc Tukey t-tests. The Kruskal-
Wallis nonparametric analysis was used for data presented as
percentages. Differences in clinical and histological scores were
analyzed using the Mann-Whitney U-test. All analyses were
performed using SPSS 13.0 software unless otherwise specified.
P-values less than 0.05 were considered to be statistically
significant. All statistical graphs were generated with GraphPad
Prism Version 4.0 (GraphPad Prism Software, Inc., San Diego,
CA, USA).
RESULTS
Reg-2 has Greater BBB Permeability
than CNTF
An LC-MS-MS analysis revealed that the mean 13C abundance
in normal control brain tissue was 1.09%, and this finding was
consistent with a previous report (Ross et al., 2003). Thirty
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FIGURE 4 | CNTF treatment and Reg-2 treatment prevent demyelination, axonal loss, and neuronal apoptosis. Representative electron micrographs at
2 weeks and 8 weeks post-immunization. BC, Brain cortex; SC, Spinal cord. (A) Normal myelinated axons exhibiting dark, ring-shaped myelin sheaths. (B) Sheath
splitting and vacuoles showing loose and fused changes were observed in vehicle-treated rats at 2 weeks post-immunization. In CNTF- (C) and Reg-2-treated
(D) rats at 2 weeks post-immunization, some vacuolated sheaths were observed, but most of the dark ring-shaped myelin sheath structures were retained.
(E) Myelin lamellae undergoing vesicular disintegration and concurrent remyelination (red arrow) were observed in vehicle-treated rats at 8 weeks post-immunization.
In contrast, CNTF- (F) and Reg-2-treated (G) rats showed a greater number of newly formed myelin sheaths (blue arrow) at 8 weeks post-immunization. (H) Normal
nuclei of neurons with uncondensed chromatin. (I) In vehicle-treated rats, apoptotic neurons with remarkably shrunken nuclei containing condensed, fragmented,
and marginalized nuclear chromatin were observed. In CNTF- (J) and Reg-2-treated (K) rats, the ultrastructure of myelin was retained and appeared relatively
normal. (A–G) Scale bar = 1 µm; (H–K) Scale bar = 2 µm.
minutes after intravenous injection of CNTF or Reg-2, the mean
13C abundance in brain parenchyma was 1.15% in the 13C-CNTF
group and 1.26% in the 13C-Reg-2 group; the latter value was
significantly higher than the former (P < 0.05).
Both CNTF Treatment and Reg-2
Treatment Reduce the Severity of EAE
c-SEP and c-MEP latencies were used as surrogates of conduction
speed, and amplitudes indicated the number of surviving fibers.
EAE induction prolonged the latencies to waveform initiation
and decreased the peak amplitudes of both c-SEPs (Tables 1, 2)
and c-MEPs (Tables 3, 4) in EAE rats. Both CNTF treatment
and Reg-2 treatment significantly attenuated disease-associated
delays in latency and decreases in amplitude. Furthermore, there
was no difference between CNTF treatment and Reg-2 treatment
in terms of these effects (P > 0.05).
Per functional scoring, EAE symptoms appeared in vehicle-
treated rats on days 7–9 post-immunization and peaked
(average clinical score = 3.5–4.0) at 2 weeks post-immunization.
Thereafter, clinical scores gradually declined and acute EAE rats
underwent spontaneous recovery by 8 weeks post-immunization
(average clinical score = 1.5–2.0). The disease progression
of CNTF- and Reg-2-treated rats was similar to that of
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FIGURE 5 | CNTF treatment and Reg-2 treatment alleviate axonal loss at both 2 weeks and 8 weeks post-immunization. (A,B) Normal control. (C,D,I,J)
Numerous axons undergoing gradual loss and exhibiting deformed and ovoid formations in vehicle-treated rats at 2 weeks and 8 weeks post-immunization, indicated
by arrows. In CNTF- (E,F,K,L) and Reg-2-(G,H,M,N) treated rats, more axons were retained relative to the vehicle-treated group at both 2 weeks (O) and 8 weeks
(P) post-immunization, as estimated by axonal loss score. (a) P < 0.05 vs. vehicle-treated EAE rats; (b) P < 0.05 vs. CNTF-treated EAE rats. Scale bar = 100 µm.
vehicle-treated rats, but the disease onset was more gradual
and the peak disease severity was delayed to 3 weeks post-
immunization. Furthermore, clinical scores were significantly
lower in CNTF- and Reg-2-treated rats than in vehicle-treated
rats at all time points (Figure 1).
CNTF Treatment and Reg-2 Treatment
Limit the Extent of CNS Infiltration and
Inflammation in EAE
To quantify inflammatory cell infiltration into the CNS, we
performed immunostaining for CD4, a marker of extravasated
T lymphocytes, and CD68, a marker of activated microglia
and extravasated macrophages. At the peak stage of acute EAE
(2 weeks post-immunization), vehicle-treated rats exhibited a
significant increase in the number of infiltrating inflammatory
cells. When compared with the normal group (Figures 2A,E),
diffuse infiltration was observed not only around the blood
vessels, but also throughout the brain and spinal cord
parenchymata (Figures 2B,F,G; Supplementary Figure 1C). Less
severe perivascular and parenchymal infiltration was observed in
CNTF-treated rats (Figures 2C,H; Supplementary Figure 1D)
and Reg-2-treated rats (Figures 2D,I; Supplementary Figure 1E)
at this time point. In addition, the inflammatory scores of CNTF-
and Reg-2-treated rats were also significantly lower than that of
vehicle-treated rats at 2 weeks post-immunization (Figure 2K).
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FIGURE 6 | CNTF treatment and Reg-2 treatment effectively reduce the expression of pro-inflammatory factors. The pro-inflammatory factors TNF-α
(A,B), NF-κB (E,F), COX-2 (G,H), IFN-γ (I,J), and IL-2 (K,L) were attenuated while GAP-43 (C,D) and the anti-inflammatory cytokines IL-4 (M,N) and TGF-β (O,P)
were increased in CNTF- and Reg-2-treated rats. (a) P < 0.05 vs. normal control; (b) P < 0.05 vs. vehicle-treated EAE rats. (E–H) (a) P < 0.05 vs. vehicle-treated
EAE rats.
At 8 weeks post-immunization, inflammatory cell infiltration
and inflammatory scores were increased in CNTF- and Reg-2-
treated rats (Figure 2L, Supplementary Figures 1G,H), but
remained significantly lower than those observed in vehicle-
treated rats. (Figure 2L, P < 0.05). Moreover, the co-localization
of CCR3 (a marker for Th2-polarized cells) and CD4 on
infiltrating T cells was visibly increased at this time point relative
to 2 weeks post-immunization (Figures 2I,J).
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FIGURE 7 | The expression of pro-inflammatory factors in response to CNTF treatment and Reg-2 treatment. At 2 weeks post-immunization, the
expression of TNF-α (A–D, TRIFC-conjugated immunofluorescent staining, red), GAP-43 (E–H, FITC-conjugated immunofluorescent staining, green), NF-κB (I–L),
and COX-2 (M–P, immunohistochemical staining counterstained with hematoxylin) were increased in vehicle-treated rats relative to normal control rats. The
expression of pro-inflammatory factors was attenuated while the expression of GAP-43 was enhanced in both CNTF- and Reg-2-treated rats.
CNTF Treatment and Reg-2 Treatment
Inhibit Demyelination and Improve
Remyelination in EAE
Immunohistochemical labeling of MBP was used as a
surrogate indicator of myelination (Figure 3). Large confluent
areas of demyelination were observed in vehicle-treated
EAE rats relative to normal rats at 2 weeks and 8 weeks
post-immunization (Figures 3A–D). CNTF or Reg-2
treatment attenuated the development of demyelination
relative to vehicle-treated rats at these time points
(Figure 3).
Transmission electron microscopy examination further
revealed that, at 2 weeks post-immunization in vehicle-treated
rats, a considerable amount of the myelin sheath displayed
splitting and vacuolar changes when compared with the normal
group (Figure 4A); axons were shrunken and covered by
disrupted myelin (Figure 4B). In contrast, CNTF- and Reg-2-
treated rats exhibited lesser vacuolar changes at 2 weeks post-
immunization (Figures 4C,D). At 8 weeks post-immunization,
demyelination and remyelination appeared simultaneously
in vehicle-treated rats; additionally, nuclei showed signs of
apoptosis, including condensed, fragmented, and marginalized
nuclear chromatin (Figures 4E,I). A greater number of
remyelinated fibers was observed in CNTF- and Reg-2-treated
rats (Figures 4F,G); additionally, neighboring nuclei presented
a normal ultrastructure (Figures 4J,K) just like the nuclei of
normal group (Figure 4H).
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FIGURE 8 | Effect of CNTF and Reg-2 on apoptosis at 8 weeks post-immunization. (A,C) In vehicle-treated rats, expression of the pro-apoptotic regulator
BAX was markedly increased and expression of the anti-apoptotic regulator BCL-2 was decreased at 8 weeks post-immunization. This effect was reversed by CNTF
or Reg-2 treatment. (B,D) (a) P < 0.05 vs. the normal control; (b) P < 0.05 vs. vehicle-treated EAE rats.
CNTF Treatment and Reg-2 Treatment
Prevent Axon Loss
Bielschowsky’s silver staining revealed reductions in CNS axonal
density in vehicle-treated rats relative to normal rats at 2 weeks
(Figures 5C,D) and 8 weeks (Figures 5I,J) post-immunization.
Vehicle-treated rats also exhibited axonal loss and injured
axons displaying swelling, deformation, and ovoid formations
(arrow in Figure 5D) relative to normal rats (Figures 5A,B)
at 2 weeks post-immunization. At 8 weeks post-immunization
in the vehicle-treated group, many neurons exhibited almost
complete axonal loss, such that only the injured cell bodies
were observed (arrows in Figure 5I). A larger number of axons
with relatively normal formation were observed in CNTF- and
Reg-2-treated rats than in vehicle-treated rats (Figure 5). Axonal
loss scores (Figures 5O,P) also confirmed the axon-protective
effects of CNTF and Reg-2 treatments. Moreover, there was no
difference between the axonal loss scores of CNTF- and Reg-2-
treated rats (Figures 5O,P).
CNTF Treatment and Reg-2 Treatment
Suppress the Expression of
Pro-Inflammatory Factors and Increase the
Expression of Anti-Inflammatory Factors
in EAE
COX-2, NF-κB, TNF-α, and GAP-43 were detected in CNS
tissues by immunostaining (Figures 6, 7), and TGF-β, IFN-γ,
IL-2, and IL-4 were measured in serum by ELISA (Figure 6).
The expression of important pro-inflammatory factors such
as COX-2 and NF-κB and cytokines such as TNF-α and
IL-2 were significantly increased in vehicle-treated EAE rats
at 2 weeks and 8 weeks post-immunization. CNTF and
Reg-2 treatments markedly reduced the expression of these
factors (Figures 6, 7). Conversely, anti-inflammatory cytokines
such as IL-4 and TGF-β were clearly downregulated in
vehicle-treated EAE rats relative to normal rats at 2 weeks
and 8 weeks post-immunization. In contrast, anti-inflammatory
cytokines were increased in CNTF- and Reg-2- treated rats
(Figure 6).
EAE-induction fractionally increased the expression of GAP-
43 in the early stages of disease, but GAP-43 expression decreased
as EAE progressed. Of note, CNTF and Reg-2 treatments
markedly upregulated the expression of GAP-43 at both 2 weeks
and 8 weeks post-immunization (Figures 6C,D, 7E–H). There
were no significant differences observed between CNTF- and
Reg-2-treated rats (Figures 6, 7).
CNTF Treatment and Reg-2 Treatment
Reduce Apoptosis and Neuronal
Loss in EAE
Western blotting showed that, at 8 weeks post-immunization
in vehicle-treated rats, expression of the proapoptotic
regulator BAX was clearly upregulated while expression of
the antiapoptotic regulator BCL-2 was markedly downregulated
(Figure 8). This phenomenon was reversed by CNTF or Reg-2
treatment.
Visible neuronal loss and activated caspase-3 expression
was also observed in the CNS of vehicle-treated rats relative
to normal rats at 8 weeks post-immunization (Figure 9). In
CNTF- and Reg-2-treated rats, a larger number of neurons
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FIGURE 9 | CNTF treatment and Reg-2 treatment reduce apoptosis and neuronal loss in the spinal cord and brain cortex. (A–H) Visible neuronal loss
was observed in the CNS of the vehicle-treated rats at 8 weeks post-immunization (C–D) relative to normal animals (A–B). In CNTF- and Reg-2-treated EAE rats, a
greater number of neurons was observed in the anterior horn of the spinal cord and in the motor cortex (E–H). Nissl staining, scale bar = 100 mm. (I) The calculated
number of surviving neurons at 8 weeks post-immunization (each value is presented as a percentage of the normal control). (a) P < 0.05 vs. normal control; (b) P <
0.05 vs. vehicle-treated EAE rats. (J,K) The number of caspase-3-labeled neurons at 8 weeks post-immunization. (a) P < 0.05 vs. normal control; (b) P < 0.05 vs.
vehicle-treated EAE rats.
were visualized in the anterior horn of the spinal cord and
in the motor cortex (Figure 9). No significant differences
were observed between CNTF- and Reg-2-treated rats
(Figure 9).
DISCUSSION
In MS and EAE, myelin repair is generally insufficient
despite the survival of some oligodendrocytes in demyelinating
plaques (Stankoff et al., 2002). In the present model of
rodent EAE, we noted the appearance of remyelination
during the recovery stage at 8 weeks post-immunization, but
remyelination alone was insufficient to produce functional
recovery in vehicle-treated rats. Therefore, the identification
of functionally significant therapeutic targets is an obstacle to
MS treatment.
CNTF was originally identified as a survival factor in isolated
neurons, and was later additionally identified as a factor for
the differentiation, maturation, and survival of oligodendrocytes.
CNTF-deficient mice are thus reported to demonstrate poor
recovery from the acute phase of EAE due to extensive
oligodendrocyte apoptosis (Linker et al., 2002). Moreover, a
greater extent of myelin vacuolar dystrophy and axonal damage
has been reported in CNTF-deficient mice (Linker et al., 2002).
In the present study, sustained delivery of recombinant rat
CNTF or Reg-2 was used to treat acute EAE. Both CNTF
and Reg-2 exerted direct neuroprotective effects, alleviating
demyelination, preventing axon loss, and reducing neuronal
death. Both treatments also led to a delay in disease onset and
clinical manifestation.
CNTF and Reg-2 treatments reduced the number of
infiltrating T cells and activated macrophages including
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microglia during the early stages of EAE. Previous studies have
shown that CNTF inhibits the endotoxin-mediated synthesis
of pro-inflammatory mediators IL-1 and prostaglandin E2 in a
receptor-dependent fashion (Shapiro et al., 1994). Additionally,
transplantation of mesenchymal stem cells transfected with
CNTF decreases serum TNF-α and IFN-γ and reduces the
infiltration of inflammatory and CD3-positive cells into EAE
lesions (Lu et al., 2009). Moreover, endogenous CNTF is
thought to have a centrally mediated anti-inflammatory role
for inhibiting the production of TNF-α and IL-6 (Meazza et al.,
1997). Our data are consistent with these findings. CNTF and
Reg-2 administration significantly downregulated the expression
of pro-inflammatory cytokines TNF-α, IL-2, and IFN-γ, as well
as inflammatory pathway-related transcription factors such as
COX-2 and NF-κB. Conversely, these treatments increased the
expression of anti-inflammatory cytokines IL-4 and TGF-β.
These data suggest a possible immunosuppressive effect on
CD4+ T helper1 (Th1) lymphocytes that favors the activity of
CD4+ Th2 cells (Zhang et al., 2006; Garay et al., 2008).
At 8 weeks post-immunization (6 weeks after the cessation
of treatment), inflammatory infiltration increased in CNTF-
and Reg-2-treated rats; however, it appeared that the anti-
inflammatory effects of CNTF and Reg-2 in the early stage
had already improved the CNS microenvironment. As a result,
more neurons were retained in the CNTF- and Reg-2-treated
groups relative to the vehicle-treated group. Moreover, although
CNTF and Reg-2 did not appear to have long-lasting effects
on inflammation in the late stage, their neurotrophic effects
persisted and appeared to alleviate demyelination, prevent axon
loss, and reduce neuronal death. Thus even at 8 weeks post-
immunization, improvements were observed in remyelination
as well as axonal and neuronal survival. We speculated that
at this stage, infiltrating lymphocytes were likely to be Th2-
polarized cells. This hypothesis was confirmed by the observation
of double-labeled CD4-positive and CCR3-positive cells in the
CNS, which indicated the infiltration of Th2-polarized rather
than Th1-polarized lymphocytes. These data suggest that CNTF
treatment and Reg-2 treatment similarly retain the ability to
alleviate demyelination, axonal loss, and neuronal death even
after treatment cessation.
NF-κB is a transcription factor that is central to immunity and
inflammation. This protein regulates the expression of a number
of genes related to cytokines and apoptosis (Yin et al., 2012).
TNF-α has an established role in oligodendrocyte apoptosis and
myelin destruction in EAE (Linker et al., 2002). Inflammation-
mediated damage and apoptosis have also been attributed to the
overproduction of COX-2 (Song et al., 2014). Given that the
expression of these pre-apoptotic factors was effectively reduced
by CNTF and Reg-2 treatments, we anticipated the observation
of increased anti-apoptotic BCL-2 and decreased pro-apoptotic
BAX and caspase-3. Indeed, these findings are in accordance
with the rescue of oligodendrocytes and neurons by direct
neurotrophic effects and an improved cellularmicroenvironment
(Yu et al., 2010; Malairaman et al., 2014).
Regenerative sprouting and axon growth are regulated by
the intrinsic growth potential of the neuron as well as the
inhibitory environment present in the myelinated adult CNS
(Fitch and Silver, 2008). GAP-43, also known as neuromodulin,
is a protein considered to be crucial for axonal regeneration
(Jacobson et al., 1986). Neurons in a regenerative state show
increased expression of GAP-43, while decreases in GAP-43
expression are thought to result from neuronal damage (Saal
et al., 2016). Thus, changes in GAP-43 expression likely reflect
the induction of a nerve regenerative program (Ceber et al.,
2015). In our study, we observed that CNTF and Reg-2
treatments prolonged initial increases in GAP-43 expression
induced by EAE induction. Thus supporting the expression of
GAP-43 may have played a role in the ability of CNTF and Reg-2
to prevent axon degeneration and promote axon regeneration
in EAE.
Previous research has revealed that purified Reg-2 has
neurotrophic effects on subpopulations of motoneurons
(Nishimune et al., 2000). As an obligatory intermediate in the
survival signaling pathway mediated by CNTF (Emerich, 2004),
Reg-2 is also itself a neurotrophic factor (Nishimune et al.,
2000). Our studies confirm these observations: Reg-2 and CNTF
produced similar inflammatory suppression, axon and myelin
preservation, neuronal survival, and functional improvement in
the acute phase of EAE. With a smaller molecular weight and
improved penetration into the brain parenchyma, Reg-2 may
be a useful substitute for CNTF and help to avoid the many
adverse effects of direct CNTF application in EAE and MS
(Kuhlmann et al., 2006).
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Supplementary Figure 1 | The effect of ciliary neurotrophic factor
(CNTF) treatment and regeneration gene protein 2 (Reg-2) treatment
on inflammatory cell infiltration. Two weeks post-immunization,
inflammatory cell infiltration was observed surrounding the blood vessels and
in the CNS parenchymata of vehicle-treated rats (B–C) relative to normal
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treatments alleviated inflammatory cell infiltration (D,E). However, at 8 weeks
post-immunization (F), 6 weeks after the cessation of treatment, inflammatory
cell infiltration increased in CNTF- (G) and Reg-2-treated rats (H) relative to
that observed at 2 weeks post-immunization. Nissl staining, Scale
bar = 100 mm.
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